Orthofix Medical Inc. (OFIX)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 884624 · fiscal year ends in Dec
Closing price $9.07 on 30 Oct 2026; 52-week range $8.64 to $16.20.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $833.2M
- Revenue growth
- 3.0%
- Net income, last twelve months
- -$61.7M
- Earnings per share
- -$1.54
- Gross margin
- 71.3%
- Operating margin
- -4.7%
- Net margin
- -7.4%
- Free cash flow
- -$27.8M
- Return on equity
- -14.4%
- Market value
- $369.6M
- Cash
- $103.8M
- Debt
- $221.6M
- Debt to equity
- 0.52
- Shares outstanding
- 40.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $822.3M | -$81.4M | -$92.2M | -$2.33 | -$1.3M | 10-K filed 24 Feb 2026 |
| FY2024 | 31 Dec 2024 | $799.5M | -$84.6M | -$126.0M | -$3.30 | -$9.1M | 10-K filed 25 Feb 2025 |
| FY2023 | 31 Dec 2023 | $746.6M | -$139.1M | -$151.4M | -$4.12 | -$106.0M | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $460.7M | -$13.3M | -$19.7M | -$0.98 | -$32.9M | 10-K filed 6 Mar 2023 |
| FY2021 | 31 Dec 2021 | $464.5M | -$8.3M | -$38.4M | -$1.95 | $690.0K | 10-K filed 25 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $210.9M | -$15.8M | -$0.39 |
| Q1 FY2026 | 31 Mar 2026 | $196.7M | -$20.9M | -$0.52 |
| Q4 FY2025 | 31 Dec 2025 | $219.9M | -$2.2M | -$0.06 |
| Q3 FY2025 | 30 Sep 2025 | $205.6M | -$22.8M | -$0.57 |
| Q2 FY2025 | 30 Jun 2025 | $203.1M | -$14.1M | -$0.36 |
| Q1 FY2025 | 31 Mar 2025 | $193.6M | -$53.1M | -$1.35 |
| Q4 FY2024 | 31 Dec 2024 | $215.7M | -$29.1M | -$0.75 |
| Q3 FY2024 | 30 Sep 2024 | $196.6M | -$27.4M | -$0.71 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Global Spine | $687.7M | 83.6% |
| Global Limb Reconstruction | $134.7M | 16.4% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $684.1M | 83.2% |
| Others | $76.7M | 9.3% |
| Italy | $22.3M | 2.7% |
| United Kingdom | $13.3M | 1.6% |
| France | $12.0M | 1.5% |
| Germany | $9.1M | 1.1% |
| Brazil | $4.8M | 0.6% |
Company events
The newest 8-K filings of 324 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 2 Jul 2026 | 8-K | Investor update | 7.01 |
| 11 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 21 May 2026 | 8-K | Investor update | 7.01 |
| 5 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 9 Apr 2026 | 8-K | Results, Leadership change | 2.02, 5.02, 9.01 |
| 24 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 4 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 5 Aug 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 20 Jun 2025 | 8-K | Shareholder vote | 5.07, 9.01 |
| 6 May 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 7 Apr 2025 | 8-K | Material agreement, Agreement ended | 1.01, 1.02 |
Every filing
The newest filings with the SEC of 698 held.
| Filed | Form | Period |
|---|---|---|
| 5 Aug 2026 | S-8 | – |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 2 Jul 2026 | 8-K | 1 Jul 2026 |
| 11 Jun 2026 | 8-K | 11 Jun 2026 |
| 29 May 2026 | SD | – |
| 21 May 2026 | 8-K | 21 May 2026 |
| 5 May 2026 | 10-Q | 31 Mar 2026 |
| 5 May 2026 | 8-K | 5 May 2026 |
| 29 Apr 2026 | DEFA14A | – |
| 29 Apr 2026 | DEF 14A | 29 Apr 2026 |
| 9 Apr 2026 | 8-K | 9 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 1 Oct 2026 | Fisher Patrick, President, Global Limb Recon | Sale under a trading plan | 150 | $9.44 | $1.4K | 50,919 | 5 Oct 2026 |
| 21 Sep 2026 | Juniper Investment Company, Llc, 10% owner | Sale outside a trading plan | 190,000 | $8.86 | $1.7M | 3,771,216 | 22 Sep 2026 |
| 18 Sep 2026 | Juniper Investment Company, Llc, 10% owner | Sale outside a trading plan | 120,000 | $8.74 | $1.0M | 3,581,216 | 22 Sep 2026 |
| 1 Sep 2026 | Fisher Patrick, President, Global Limb Recon | Sale under a trading plan | 150 | $9.39 | $1.4K | 51,069 | 3 Sep 2026 |
| 18 Aug 2026 | Fisher Patrick, President, Global Limb Recon | Sale outside a trading plan | 1,295 | $10.09 | $13.1K | 51,219 | 20 Aug 2026 |
| 17 Aug 2026 | Juniper Investment Company, Llc, 10% owner | Sale outside a trading plan | 20,000 | $10.01 | $200.3K | 84,926 | 18 Aug 2026 |
| 14 Aug 2026 | Juniper Investment Company, Llc, 10% owner | Sale outside a trading plan | 19,500 | $10.38 | $202.5K | 64,926 | 18 Aug 2026 |
| 18 Jun 2026 | Mcpherron Aviva, Pres, Global Ops & Qual | Sale outside a trading plan | 3,670 | $9.38 | $34.4K | 66,330 | 22 Jun 2026 |
| 22 May 2026 | Juniper Investment Company, Llc, 10% owner | Sale outside a trading plan | 242,000 | $10.70 | $2.6M | 3,461,216 | 29 May 2026 |
| 7 May 2026 | Henneman John B Iii, Director | Purchase | 5,000 | $12.26 | $61.3K | 90,809 | 8 May 2026 |
| 7 May 2026 | Engine Capital Management, Lp, 10% owner | Purchase | 18,192 | $12.20 | $221.9K | 3,839,477 | 7 May 2026 |
| 7 May 2026 | Engine Capital Management, Lp, 10% owner | Purchase | 9,096 | $12.15 | $110.5K | 3,848,573 | 7 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 1 Sep 2026 | PATRICK FISHER, Officer | 450 | $4.2K | 1 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Armistice Capital, LLC | 13G amended | 8.01% | 3.3M |
| 27 May 2026 | Juniper Targeted Opportunity Fund, L.P. | 13D amended | 11% | 4.4M |
| 15 May 2026 | Armistice Capital, LLC | 13G amended | 6.73% | 2.7M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Armistice Capital, LLC | 13G amended | 6.69% | 2.6M |
| 13 Feb 2026 | Juniper Targeted Opportunity Fund, L.P. | 13D amended | 9.6% | 3.8M |
| 14 Nov 2025 | Armistice Capital, LLC | 13G amended | 5.65% | 2.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.4M | -2.08% | 5.79 |
| 30 Sep 2026 | 2.4M | -2.56% | 5.49 |
| 15 Sep 2026 | 2.5M | +5.51% | 7.1 |
| 31 Aug 2026 | 2.4M | +14.54% | 9.2 |
| 14 Aug 2026 | 2.1M | -2.32% | 4.34 |
| 31 Jul 2026 | 2.1M | -15.42% | 7.42 |
| 15 Jul 2026 | 2.5M | +6.2% | 6.2 |
| 30 Jun 2026 | 2.4M | +18.49% | 5.46 |
Funds that hold it
From each fund's latest Form 13F.
171 funds held it at 30 Jun 2026: 83 added and 37 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Engine Capital Management, LP | 4,575,675 | $41.8M | +184,896 |
| Juniper Investment Company, LLC | 4,442,543 | $40.6M | +465,584 |
| Rubric Capital Management LP | 3,721,715 | $34.0M | 0 |
| BlackRock, Inc. | 3,326,560 | $30.4M | +118,771 |
| Paradigm Capital Management Inc. | 3,300,499 | $30.2M | -4,400 |
| Armistice Capital, LLC | 3,264,000 | $29.8M | +564,000 |
| Vanguard Capital Management LLC | 1,731,108 | $15.8M | +75,659 |
| Geode Capital Management, LLC | 1,048,081 | $9.6M | +109,196 |
| State Street Corp. | 953,148 | $8.7M | +45,716 |
| AQR Capital Management LLC | 887,282 | $8.1M | +698,158 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B